Actim Partus is a clinically validated rapid test kit that helps assess the risk of spontaneous preterm birth in pregnant women, including those presenting with symptoms of preterm labor.
The test detects phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1), a biomarker released during cervical ripening and early labor. A positive result indicates an increased risk of delivery within the next 7–10 days, allowing clinicians to make informed decisions regarding antenatal corticosteroids, tocolysis, magnesium sulfate, referral, or hospitalization.
Actim Partus provides reliable results within minutes and is easy to perform at the bedside, making it particularly valuable in both high- and low-resource healthcare settings. By reducing unnecessary admissions and improving targeted care, Actim Partus supports better outcomes for mothers and newborns while optimizing healthcare resources.
Key benefits:
- Predicts risk of preterm birth within 7–10 days
- Rapid, point-of-care results
- Supports timely and targeted clinical interventions.
- Suitable for use in diverse healthcare settings
